Gitlife Biotech appoints Beatrix Ellis as CEO
Commercial strategy, business development and capital raising experience will lead the spin out's next phase of growth.
31 October 2024
GitLife Biotech Ltd., a pioneering synthetic biology company dedicated to establishing the global standards for safeguarding engineered bio-assets throughout their lifecycle and beyond, is pleased to announce the appointment of Beatrix Ellis as its new Chief Executive Officer.
Beatrix Ellis brings extensive experience in commercial strategy and a proven record in business development and capital raising, making her a strong fit to guide GitLife’s next phase of growth.
She will oversee the company’s initiatives to secure investment and expand its innovative technologies, including CellRepo™ and DNA GenoSignatures®, that together support robust and secure rights management of biological assets providing proof of ownership and provenance, positioning the company for rapid scale in the synthetic biology space.
Shaping engineering biology's future
“Beatrix’s appointment marks a pivotal moment for GitLife,” said Prof Natalio Krasnogor (CTO). “As we focus on fundraising and advancing our biosecurity and IP protection technology, her experience, networks and knowledge of the sector will ensure GitLife continues to shape engineering biology’s future.”
By engaging with a diverse array of stakeholders, including leading biotech firms and academic institutions, GitLife addresses critical needs, from protecting R&D assets to preserving strain collections and legacy data. The company is committed to expanding the reach of its biosecurity solutions, helping clients maintain secure and transparent biological assets.
For further information, please contact: media@gitlifebiotech.com
